Antithrombin- erstatning under indgivelse af koagulationshæmmere, der forstærker antithrombins koagulationshæmmende virkning (f. eks. heparin, lavmolekylært heparin), kan øge risikoen for blødning.
Antithrombin replacement during administration of anticoagulants that potentiate the anticoagulant activity of antithrombin (e. g., heparin, low molecular weight heparin), may increase the risk of bleeding.